Fenestrated endovascular aneurysm repair and open surgical repair for the treatment of juxtarenal aortic aneurysms. 2019

Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
Service de Chirurgie Vasculaire, Assistance Publique Hôpitaux de Marseille-Hôpital de la Timone, Faculté de Médecine de Marseille, Aix-Marseille Université, Marseille, France.

OBJECTIVE The objective of this study was to compare surgical risk and early and late mortality of patients treated for anatomically classified juxtarenal aortic aneurysms (JRAs) by fenestrated endovascular aneurysm repair (F-EVAR) or open surgical repair (OSR) during a period when the two treatments were available and to validate an institutional algorithm for JRA repair. METHODS We retrospectively included all patients treated electively in our center between January 2005 and December 2015 for JRAs classified into three anatomic categories, excluding suprarenal aneurysms. Lee score and American Society of Anesthesiologists (ASA) class evaluated preoperative surgical risk. We compared clinical and radiologic parameters between the patients treated by F-EVAR and those treated by OSR. The primary study end point was 30-day mortality. We also compared 5-year survival. RESULTS From 2005 to 2015, there were 191 patients separated into two groups, one treated by OSR (n = 134; mean age, 69 years) and the other treated by F-EVAR (n = 57; mean age, 74 years). Patients of the F-EVAR group were significantly older (P = .001). Intensive care unit length of stay was significantly higher in the OSR group (3.4 days vs 1.5 days; P = .01). Surgical risk was significantly higher in the F-EVAR group as measured by Lee score ≥2 (OSR, 8.9 %; F-EVAR, 21%; P = .02) and ASA class 3 and class 4 (OSR, 32.8%; F-EVAR, 73.6%; P = .001), whereas 30-day postoperative mortality was not significantly different (OSR, 1.5%; F-EVAR, 0%; P = .394). The 5-year survival was not significantly different in the two groups (OSR, 82.1%; F-EVAR, 69.2%). CONCLUSIONS In this study, despite a higher surgical risk by Lee score and higher ASA class in the group of patients treated by F-EVAR, postoperative mortality was not significantly different between these groups. In our opinion, F-EVAR and OSR of JRA are complementary.

UI MeSH Term Description Entries
D008297 Male Males
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D001807 Blood Vessel Prosthesis Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels. Vascular Prosthesis,Blood Vessel Prostheses,Tissue-Engineered Vascular Graft,Graft, Tissue-Engineered Vascular,Grafts, Tissue-Engineered Vascular,Prostheses, Blood Vessel,Prostheses, Vascular,Prosthesis, Blood Vessel,Prosthesis, Vascular,Tissue Engineered Vascular Graft,Tissue-Engineered Vascular Grafts,Vascular Graft, Tissue-Engineered,Vascular Grafts, Tissue-Engineered,Vascular Prostheses,Vessel Prostheses, Blood,Vessel Prosthesis, Blood
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
January 2015, Journal of vascular surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
March 2008, The British journal of surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
February 2013, Chinese medical journal,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
October 2019, BJS open,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
January 2014, Journal of vascular surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
October 2021, Journal of vascular surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
April 2022, Journal of vascular surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
August 2021, Annals of vascular surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
March 2009, Journal of vascular surgery,
Raphael Soler, and Michel A Bartoli, and Christopher Faries, and Julien Mancini, and Gabrielle Sarlon-Bartoli, and Stephan Haulon, and Pierre Edouard Magnan
February 2022, The Journal of cardiovascular surgery,
Copied contents to your clipboard!